Company intelligence / Profile preview
Provectus Biopharmaceuticals
- Ownership
- Public · PVCT
- Development stage
- Other
Overview
Provectus’s lead candidate PV-10 has shown promising results in early clinical trials for melanoma and other cancers. The company has demonstrated systemic immune activation in metastatic liver cancers. Preclinical data suggest oral administration of rose bengal may be effective against a range of solid tumors by downregulating WNK1 and Wnt signaling pathways. Dermatology program PH-10 targets inflammatory skin diseases with topical application[2][3][6]. Ophthalmic applications are being advanced through a subsidiary.
- Therapeutic areas
- DermatologyOphthalmologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $21.9M
- Total revenue
- $336.1K
- Enterprise value
- $24.2M
Beyond the preview
Go deeper on Provectus Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Provectus Biopharmaceuticals.